Statistical assessment of in vitro drug release kinetics and quality evaluation of desloratadine orally disintegrating generic tablets available in Bangladesh

Abstract

The objective of the present study was to compare the in vitro equivalence of different orally disintegrating tablets (ODT) of Desloratadine (DES) available in Bangladesh pharmaceutical market with the reference brand. The in vitro dissolution study was carried out using the United States Pharmacopoeia (USP) paddle method and a comparative study were also carried out with the reference brand. Other pharmacopoeial and non-pharmacopoeial quality assessment parameters including hardness, friability, water absorption ratio, and disintegration time etc. were also evaluated. From the results of the dissolution profile of the commercially available products, it found majority of the products didn’t exhibited compendial requirements in dissolution behavior to the reference brand with model-independent approach (f₂ > 50, f₁ < 15) and showed statistically significant differences. Additionally, the data of different physical quality parameters revealed that all commercial products complied with the official specifications. From these findings, it could be suggested that the DES-ODT formulations’ available in the Bangladesh market could be prescribed; however additional experiments might require to clarify the interchangeability among the products.

Keywords

Desloratadine dissolution orally disintegrating tablet similarity factor difference factor

Get full access to this article

View all access options for this article.

References

Chowdhury

Kabir

Alam

MM.

Allergic rhinitis, asthma and atopic diseases: Bangladesh perspective. Bangladesh J Otorhinolaryngol 1970; 14: 66–70.

Simons

FER

Simons

KJ.

Review article of current status and future directions. World Allergy Organ J 2008; 1: 145–155.

Hoyte

FCL

Katial

RK.

Antihistamine therapy in allergic rhinitis. Immunol Allergy Clin North Am 2011; 31: 509–543.

Mahdy

Webster

NR.

Histamine and antihistamines. Anaesth Intensive Care Med 2017; 18: 210–215.

Sieck

Hsu

WH.

Why are second-generation H1-antihistamines minimally sedating?

Eur J Pharmacol 2015; 765: 100–106.

Passalacqua

Canonica

GW.

A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. Clin Ther 2005; 27: 979–992.

Henz

BM.

The pharmacologic profile of desloratadine: a review. Allergy 2001; 56: 7–13.

Dyrda

NM.

Desloratadine. USA: FDA, 2015.

DuBuske

LM.

Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert Opin Pharmacother 2005; 6: 2511–2523.

10.

Limon

Kockler

Lugo

, et al. Desloratadine: a nonsedating antihistamine. Ann Pharmacother 2003; 37: 237–246.

11.

Berginc

Sibinovska

Žakelj

, et al. Biopharmaceutical classification of desloratadine – not all drugs are classified the easy way. Acta Pharm 2020; 70: 131–144.

12.

Sastry

Nyshadham

Fix

JA.

Recent technological advances in oral drug delivery – a review. Pharm Sci Technol Today 2000; 3: 138–145.

13.

Alğin Yapar

EA.

Orally disintegrating tablets: an overview. J Appl Pharm Sci 2014; 4: 118–125.

14.

Uddin

AS.

Comparative dissolution and disintegration study of different brands of linezolid 600 mg tablets available in Karachi. Pharm Anal Acta 2018; 9: 600–603.

15.

Sugano

Okazaki

Sugimoto

, et al. Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet 2007; 22: 225–254.

16.

Medina

Salazar

Hurtado

, et al. Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system. Saudi Pharm J 2014; 22: 141–147.

17.

van Hoogevest

Liu

Fahr

Drug delivery strategies for poorly water-soluble drugs: the industrial perspective. Expert Opin Drug Deliv 2011; 8: 1481–1500.

18.

Hambisa

Belew

Suleman

In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, SouthWest Ethiopia. Drug Des Devel Ther 2019; 13: 1241–1249.

19.

Bondili

Reddy

Spectroscopic method for determination of desloratadine in bulk and its tablet dosage forms. Int J Pharm Ind Res 2011; 1: 131–141.

20.

Kakade

Mannur

Ramani

, et al. Formulation and evaluation of mouth dissolving tablets of losartan potassium by direct compression techniques. Int J Res Pharm Sci 2010; 1: 290–295.

21.

The United States Pharmacopeia and National Formulary. USP 41–NF 36; The United States Pharmacopeial Convention, Inc.: Rockville, MD. Desloratadine orally disintegrating tablets revision bulletin. 2018, pp.2–4.

22.

Pabari

Ramtoola

Effect of a disintegration mechanism on wetting, water absorption, and disintegration time of orodispersible tablets. J Young Pharm 2012; 4: 157–163.

23.

Barmpalexis

Syllignaki

Kachrimanis

A study of water uptake by selected superdisintegrants from the sub-molecular to the particulate level. Pharm Dev Technol 2018; 23: 476–487.

24.

Shah

VP.

Progressive applications of dissolution, its impact, and implications in the pharmaceutical world. J Pharm Sci 2013; 102: 2895–2897.

25.

Kawabata

Wada

Nakatani

, et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm 2011; 420: 1–10.

26.

Anand

Conner

, et al. Dissolution testing for generic drugs: an FDA perspective. AAPS J 2011; 13: 328–335.

27.

Dickinson

Lee

Stott

, et al. Clinical relevance of dissolution testing in quality by design. AAPS J 2008; 10: 380–390.

28.

Anderson

Bauer

Boussac

, et al. An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. J Pharm Biomed Anal 1998; 17: 811–822.